Zag Bio

Targeting the thymus to treat autoimmunity

Cambridge, United States · Founded 2022 · $80.0M raised

Employees
11–50
Founded
2022
Business Model
B2B
Website
zagbio.com
Total Funding
$80.0M
Last Round
$80.0M Series AOct 2025
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Zag Bio develops thymus-targeted medicines intended to treat and prevent autoimmune diseases by restoring central immune tolerance. Its bifunctional antibodies deliver self-antigens to antigen-presenting cells in the thymus, engaging the natural process that trains immune cells to recognize and tolerate self and halting or preventing autoimmune attacks. The company's pipeline includes ZAG-101 for Type 1 diabetes as well as discovery programs for other autoimmune diseases.

Summary

Zag Bio is a Biotech company based in Cambridge, United States, founded in 2022. It has raised $80.0M in total across 1 round, most recently a $80.0M Series A round in Oct 2025. Investors include Polaris Partners, JDRF T1D Fund and AbbVie Ventures.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AOct 2025
$80.0M

Investors

Similar Companies

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
Isomorphic Labs

AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...

London, United Kingdom201–500Artificial Intelligence, Biotech
Series BTotal funding$2.6BMay 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Zag Bio on Indexed.vc
<a href="https://indexed.vc/companies/zag-bio"><img src="https://indexed.vc/api/badge/company/zag-bio" alt="Zag Bio on Indexed.vc" width="260" height="76" /></a>